Source comparison
Sermorelin Work for Pediatric GHD Research History: Comparison
Before writing, two clarifications: (1) this table compares sermorelin's clinical positioning across different research phases, not sermorelin vs rhGH, and (2) the "Professional Assessment" column reflects what the cumulative evidence showed at each stage. Ear
This comparison does not assign a generated winner or score.
- Before writing, two clarifications: (1) this table compares sermorelin's clinical positioning across different research phases, not sermorelin vs rhGH, and (2) the "Professional Assessment" column reflects what the cumulative evidence showed at each stage.
- Early Trials (1985–1990)
- Proof of concept. Can exogenous GHRH stimulate GH in vivo
- Sermorelin 1–10 mcg/kg SC reliably triggered GH pulses in children with partial GHD; peak GH response correlated with residual pituitary function
- Daily to twice-daily SC injection
- Mechanism validated. Sermorelin works through preserved pituitary tissue, making patient selection critical
- Multicenter Efficacy Trials (1991–1997)
- Growth velocity outcomes in idiopathic GHD
- Mean 3.8–4.6 cm/year growth acceleration vs baseline in responders; IGF-1 elevation confirmed GH axis activation
- 30 mcg/kg three times weekly SC
- Clinically meaningful efficacy in select GHD subtypes. But 15–20% non-responder rate highlighted mechanistic limits
- Diagnostic Application Studies (1995–2008)
- Sermorelin stimulation test as GHD diagnostic
- Safer than insulin tolerance test; comparable sensitivity to arginine + GHRH testing for detecting severe GHD
- Single-dose 1 mcg/kg IV for stimulation testing
- Diagnostic utility clear and FDA-approved; became standard at many pediatric endocrine centers before 2008 withdrawal
- Post-Withdrawal Era (2009–present)
- Off-label compounded use and adult applications
- Minimal new pediatric data; adult trials show nocturnal GH pulse restoration and IGF-1 normalization in GH-insufficient adults
- Variable. Typically 0.2–0.3 mg SC daily at bedtime for adults
- Efficacy evidence remains from pre-2008 trials; current use is niche and off-label with no new large-scale pediatric studies